Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | CCNK | O75909 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23125466 | 0.93 | KMT2A (0.45) | GRM1CCNT1GSTO1KMT2AMEN1 | |
| SCHEMBL23125489 | 0.83 | CCNK (0.44) | CCNT1GSTO1CCNKCDK9PTPRB | |
| SCHEMBL23125455 | 0.82 | CCNK (0.40) | GRM1CCNT1KMT2AMEN1CCNK | |
| SCHEMBL21757604 | 0.81 | CCNK (0.42) | CCNT1GSTO1CCNKCDK9PTPRB | |
| SCHEMBL21757533 | 0.79 | CCNK (0.53) | CCNT1CCNKCDK9 | |
| SCHEMBL21757531 | 0.76 | CDK9 (0.41) | CCNT1CCNKCDK9 | |
| SCHEMBL21747521 | 0.73 | CCNK (0.44) | GRM1KMT2AMEN1CCNKCDK9 | |
| SCHEMBL4879451 | 0.73 | NPC1 (0.44) | KMT2AMEN1MAPTL3MBTL1 | |
| SCHEMBL12253205 | 0.72 | GRM2 (0.39) | GRM2KMT2AMEN1 | |
| SCHEMBL21747565 | 0.71 | CCNK (0.48) | KMT2AMEN1CCNKCDK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | GRM2 3447/4885GRM1 3091/4885CCNT1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.